Your browser doesn't support javascript.
loading
Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma.
Rasmussen, Neal R; Debebe, Zufan; Wright, Tricia M; Brooks, Samira A; Sendor, Adam B; Brannon, A Rose; Hakimi, A Ari; Hsieh, James J; Choueiri, Toni K; Tamboli, Pheroze; Maranchie, Jodi K; Hinds, Peter; Wallen, Eric M; Simpson, Catherine; Norris, Jacqueline L; Janzen, William P; Rathmell, W Kimryn.
Afiliación
  • Rasmussen NR; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America.
  • Debebe Z; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America.
  • Wright TM; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America.
  • Brooks SA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America; Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America.
  • Sendor AB; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America.
  • Brannon AR; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America;
  • Hakimi AA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States of America; Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States of America.
  • Hsieh JJ; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States of America; Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States of America.
  • Choueiri TK; Department of Medical Oncology and Kidney Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States of America.
  • Tamboli P; Department of Pathology, MD Anderson Cancer Center, Houston, Texas, 77030, United States of America.
  • Maranchie JK; Department of Urologic Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15219, United States of America.
  • Hinds P; Department of Urologic Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15219, United States of America.
  • Wallen EM; Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America.
  • Simpson C; Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America.
  • Norris JL; Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America.
  • Janzen WP; Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America.
  • Rathmell WK; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America; Departments of Medicine and Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States of America.
PLoS One ; 9(12): e116101, 2014.
Article en En | MEDLINE | ID: mdl-25542006
Ror2 is a Wnt ligand receptor that is overexpressed in a variety of tumors including clear cell renal cell carcinoma (ccRCC). Here we demonstrate that expression of wild type Ror2 results in increased tumorigenic properties in in vitro cell culture and in vivo xenograft models. In addition, Ror2 expression produced positive changes in both cell migration and invasion, which were dependent on matrix metalloprotease 2 (MMP2) activity. Mutations in key regions of the kinase domain of Ror2 resulted in the abrogation of increased tumor growth, cell migration, and cell invasion observed with expression of wild-type Ror2. Finally, we examined Ror2 expression as a prognostic biomarker for ccRCC utilizing the TCGA ccRCC dataset. High expression of Ror2 showed a significant correlation with higher clinical stage, nuclear grade, and tumor stage. Furthermore, high expression of Ror2 in ccRCC patients correlated with significant lower overall survival, cancer specific survival, and recurrence free survival. Together, these findings suggest that Ror2 plays a central role in influencing the ccRCC phenotype, and can be considered as a negative prognostic biomarker and potential therapeutic target in this cancer.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Receptores Huérfanos Similares al Receptor Tirosina Quinasa / Riñón / Neoplasias Renales Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Receptores Huérfanos Similares al Receptor Tirosina Quinasa / Riñón / Neoplasias Renales Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos